Knight Therapeutics Inc.
TSX:GUD.TODrug Manufacturers - Specialty & Generic
+$0.07 today
- Market cap
- $1.14B
- Beta
- 0.07
- P/E (TTM)
- 164.6
- EPS (TTM)
- $0.06
Volume 0.04M
Average 0.10M
GUD.TO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Knight Therapeutics Inc.TSX: GUD.TO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA growth accelerates
Q1 FY2026 EBITDA of CA$26.77M rose 106.9% year over year, ahead of the -6.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 25.7% from the prior quarter. Over 3 fiscal years it compounded at +29.1% a year.
Context
- EBITDA amounted to 12.1% of revenue in FY2025, down 5.3 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of CA$97.41M (+79.2%) for the fiscal year ending Dec 2026, a step up from the -15.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- CA$26.77M+25.7% QoQ
- Last fiscal yearDec 2025
- CA$54.37M-15.6% YoY
- LTMMar 2026
- CA$65.18M-6.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +106.9% | +1784.9% | +1678.1 pp |
| 1 year | -15.6% | +79.2% | +94.7 pp |
| 3-year CAGR | +29.1% | +39.8% | +10.7 pp |
| 5-year CAGR | +26.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
CAD · from the income statement
- Latest · FY2025
- 54.37M CAD
- Year-over-year change
- -15.6%
- 4-year CAGR
- +6.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.37M | -15.6% |
| FY2024 | 2024-12-31 | 64.38M | +57.4% |
| FY2023 | 2023-12-31 | 40.9M | +61.9% |
| FY2022 | 2022-12-31 | 25.26M | -40.7% |
| FY2021 | 2021-12-31 | 42.59M | — |
EBITDA vs competitors
How GUD.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.0% is the 6th highest of 8, against a peer median of +86.8%.
- EBITDA amounts to 12.8% of revenue for GUD.TO, versus a peer median of 20.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$65.18M CAD | -6.0% | +29.1% | 12.8% | |
| LTM Mar 2026 | $60.46M USD | +510.4% | — | 23.1% | |
| LTM Mar 2026 | $25.12M USD | +96.0% | +26.0% | 49.3% | |
| LTM Mar 2026 | CA$24.15M CAD | +96.3% | +64.2% | 20.3% | |
| LTM Mar 2026 | CA$12.62M CAD | -1.2% | — | 19.0% | |
| LTM Mar 2026 | CA$9.82M CAD | -80.9% | — | 3.1% | |
| LTM Mar 2026 | -CA$40.84M CAD | -681.4% | — | 14.9% | |
| LTM Mar 2026 | -CA$63.48M CAD | +86.8% | — | 20.4% | |
| Peer median (excluding GUD.TO) | — | +86.8% | +45.1% | 20.3% | |
Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 243.48M | 293.56M | 328.2M | 371.3M | 450.09M |
| Cost of Revenue | 128.07M | 155.5M | 175.55M | 196.9M | 299.35M |
| Gross Profit | 115.41M | 138.06M | 152.65M | 174.41M | 150.74M |
| Gross Margin | 47.4% | 47.0% | 46.5% | 47.0% | 33.5% |
| Research & Development | 12.69M | 14.76M | 17.55M | 23.3M | 28.98M |
| Selling, General & Admin | 74.38M | 88.62M | 83.69M | 99.35M | 123.96M |
| Operating Expenses | 128.24M | 155.12M | 155.54M | 167.01M | 152.94M |
| Depreciation & Amortization | 47.92M | 62.62M | 50.4M | 53.11M | 56.57M |
| EBITDA | 42.59M | 25.26M | 40.9M | 64.38M | 54.37M |
| EBITDA Margin | 17.5% | 8.6% | 12.5% | 17.3% | 12.1% |
| Operating Income | (5.32M) | (2.4M) | (2.89M) | 7.4M | (2.2M) |
| Operating Margin | -2.2% | -0.8% | -0.9% | 2.0% | -0.5% |
| Interest Income | 7.38M | 10.63M | 12.58M | 10.41M | 6.21M |
| Interest Expense | 3.62M | 6.6M | 12.49M | 9.22M | 10.42M |
| Other Income / Expenses | 19.52M | (2.92M) | (19.1M) | (5.35M) | (4.5M) |
| Income Before Tax | 6.69M | (43.96M) | (21.99M) | 2.05M | (6.7M) |
| Pre-Tax Margin | 2.7% | -15.0% | -6.7% | 0.6% | -1.5% |
| Income Tax Expense | (8.99M) | (14.07M) | (5.15M) | (2.28M) | (1.33M) |
| Net Income | 15.68M | (29.89M) | (16.84M) | 4.33M | (5.37M) |
| Net Margin | 6.4% | -10.2% | -5.1% | 1.2% | -1.2% |
| EPS (Basic) | 0.13 | (0.26) | (0.16) | 0.04 | (0.05) |
| EPS (Diluted) | 0.13 | (0.26) | (0.16) | 0.04 | (0.05) |
| Weighted Avg Shares | 124.48M | 114.89M | 107.47M | 101.04M | 99.57M |
| Weighted Avg Shares (Diluted) | 124.52M | 114.89M | 107.47M | 101.44M | 99.57M |
Knight Therapeutics Inc.
TSX:GUD.TO
Intrinsic Alpha fair value
Locked
Current Price
$11.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.